RBC Capital downgraded Exelixis (EXEL) to Sector Perform from Outperform with a price target of $50, up from $45.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Truist biotech analyst holds an analyst/industry conference call
- Exelixis price target raised to $53 from $47 at H.C. Wainwright
- Exelixis’s Promising STELLAR-303 Trial Results Lead to Buy Rating and Increased Approval Probability
- NuScale, Hims & Hers, Snowflake, Advance Auto Parts, Exelixis: Trending by Analysts
- Exelixis price target raised to $50 from $42 at Jefferies